Bedfont® Scientific Ltd, then called Bedfont® Technical Instruments Ltd., was established in 1976 by Dr John Marron. It remained a one-man business until Trevor Smith joined as marketing director in March 1985. A chartered chemist with an extensive career in the chemical gas industry, Trevor channelled his ideas and innovation into the company that would, today, become the pioneer in breath analysis for medical applications.
Now, Jason Smith is the managing director, having succeeded his father, Trevor, who is now chairman, making Bedfont® a second generation family company. Jason’s aim for Bedfont® is for its family values to be shown through its dedication to customers and the core business of breath analysis, whilst continuing to provide the best service and products to improve healthcare.
Bedfont’s breath analysers include carbon monoxide (CO) monitors such as the Smokerlyzer®, used for smoking cessation, and the ToxCO®, used by emergency services, to mass screen for CO poisoning. The NObreath® FeNO monitor provides accurate analysis of airway inflammation for the control of asthma, and the Gastrolyzer® range aids in the detection of gastrointestinal disorders and food intolerances. Quick and non-invasive, breath analysis is the new blood test.
Bedfont® also has a Medi-gas Check range of portable pipeline monitors to verify the quantity and quality of piped medical gas.
Bedfont’s latest subsidiary, NewMed, specialises in Pulsed ElectroMagnetic Field (PEMF) therapy; a non-invasive and drug-free pain-relief therapy which using the Earth’s magnetic fields to stimulate cellular repair.
16th April 2018All Events